AL-S Pharma AG
One compound to proof-of-concept
AL-S Pharma AG is a special purpose company created to develop one compound to proof-of-concept. The project is fully financed by TTVM Life Science Innovation I L.P. and Neurimmune. AL-S Pharma plans to begin clinical development in 2018. Once cleared for clinical development by regulatory authorities, the AL-S Pharma compound will be tested in ALS patients.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
No news
No milestones
No Jobs
No videos and documents
AL-S Pharma AG
One compound to proof-of-concept
Website:
www.tvm-lifescience.com/portfolio/al-s-pharma-ag/
Headquarter:
Schlieren
Foundation Date:
September 2016
Technology:
- Biotech